EC approves Pharming's HAE treatment

The European Commission approved an MAA from Pharming Group N.V. (Euronext:PHARM) for Ruconest (formerly Rhucin) to treat acute attacks of hereditary angioedema (HAE). The approval triggers a EUR 5 mi...